FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2599682072> ?p ?o ?g. }

• W2599682072 abstract "e20514 Background: Skeletal-related events (SREs) including pathological fracture (PF), surgery (SB) or radiotherapy to bone (RB), or spinal cord compression (SCC) occur frequently in patients (pts) with advanced cancer and bone metastases and may cause debilitating clinical sequelae for pts. Pooled results from 3 clinical trials showed denosumab was superior to zoledronic acid (ZA) for prevention of SREs. We now evaluate the burden of SREs through pt-reported pain and analgesic use. Methods: Randomized (1:1) pts in the phase III, double-blind, placebo-controlled trials received denosumab (120 mg SC) or ZA (4 mg IV, adjusted for renal function) monthly. In this posthoc analysis, data from pts with solid tumors in the 2 treatment arms were pooled. At baseline (BL) and each monthly visit, pain was assessed via the Brief Pain Inventory (BPI; 0 no pain to 10 severe pain), and pts’ analgesic use with the Analgesic Quantification Algorithm (AQA; 0 no analgesics to 7 > 600 mg oral morphine equivalent/day). Pain and analgesic use for pts with SREs were assessed from 6 months before to 6 months after the 1 st on-study SRE. A control group was comprised of all pts without SREs; the index time was defined as the median time to each SRE type. SRE impact was assessed using a stratified Cox proportional hazards model adjusting for SREs, as time-dependent covariates, and other baseline characteristics, and reported as HR and 95% CI. Results: 1,925 pts had an on-study SRE (first SRE type: 923 PF; 829 RB, 119 SCC, 54 SB), and 3,618 pts did not. A greater proportion of pts with SREs had a BPI worst pain score > 4 (moderate/severe pain) or an AQA score ≥ 3 (strong opioid use) than did pts with no SREs. The development of SRE was associated with significantly greater risk of pain progression from no/mild pain at BL to moderate/severe pain on study (PF 1.29 [1.07, 1.57], P = 0.009; RB 2.51 [2.03, 3.10], P < 0.001; SCC 3.07 [1.83, 5.13], P < 0.001; and SB 2.75 [1.19, 6.33], P = 0.018). Conclusions: Pts who experienced on-study SREs had increased pain severity requiring stronger analgesic use. Effective treatments that delay or prevent SREs can reduce pain and the need for palliation with opioids. Clinical trial information: NCT00321464, NCT00321620, and NCT00330759." @default.
• W2599682072 created "2017-04-07" @default.
• W2599682072 creator A5009941371 @default.
• W2599682072 creator A5021375251 @default.
• W2599682072 creator A5025804381 @default.
• W2599682072 creator A5031788907 @default.
• W2599682072 creator A5034878356 @default.
• W2599682072 creator A5036227164 @default.
• W2599682072 creator A5051298107 @default.
• W2599682072 creator A5053293171 @default.
• W2599682072 creator A5056951639 @default.
• W2599682072 creator A5058586595 @default.
• W2599682072 creator A5064106888 @default.
• W2599682072 creator A5065558630 @default.
• W2599682072 creator A5068746768 @default.
• W2599682072 creator A5069697640 @default.
• W2599682072 creator A5079115955 @default.
• W2599682072 date "2013-05-20" @default.
• W2599682072 modified "2023-10-17" @default.
• W2599682072 title "Impact of skeletal-related events on pain and analgesic use in patients with solid tumors and bone metastases." @default.
• W2599682072 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.e20514" @default.
• W2599682072 hasPublicationYear "2013" @default.
• W2599682072 type Work @default.
• W2599682072 sameAs 2599682072 @default.
• W2599682072 citedByCount "0" @default.
• W2599682072 crossrefType "journal-article" @default.
• W2599682072 hasAuthorship W2599682072A5009941371 @default.
• W2599682072 hasAuthorship W2599682072A5021375251 @default.
• W2599682072 hasAuthorship W2599682072A5025804381 @default.
• W2599682072 hasAuthorship W2599682072A5031788907 @default.
• W2599682072 hasAuthorship W2599682072A5034878356 @default.
• W2599682072 hasAuthorship W2599682072A5036227164 @default.
• W2599682072 hasAuthorship W2599682072A5051298107 @default.
• W2599682072 hasAuthorship W2599682072A5053293171 @default.
• W2599682072 hasAuthorship W2599682072A5056951639 @default.
• W2599682072 hasAuthorship W2599682072A5058586595 @default.
• W2599682072 hasAuthorship W2599682072A5064106888 @default.
• W2599682072 hasAuthorship W2599682072A5065558630 @default.
• W2599682072 hasAuthorship W2599682072A5068746768 @default.
• W2599682072 hasAuthorship W2599682072A5069697640 @default.
• W2599682072 hasAuthorship W2599682072A5079115955 @default.
• W2599682072 hasConcept C121608353 @default.
• W2599682072 hasConcept C126322002 @default.
• W2599682072 hasConcept C141071460 @default.
• W2599682072 hasConcept C2776139714 @default.
• W2599682072 hasConcept C2777783956 @default.
• W2599682072 hasConcept C2779013556 @default.
• W2599682072 hasConcept C2780820201 @default.
• W2599682072 hasConcept C2993640289 @default.
• W2599682072 hasConcept C42219234 @default.
• W2599682072 hasConcept C71924100 @default.
• W2599682072 hasConceptScore W2599682072C121608353 @default.
• W2599682072 hasConceptScore W2599682072C126322002 @default.
• W2599682072 hasConceptScore W2599682072C141071460 @default.
• W2599682072 hasConceptScore W2599682072C2776139714 @default.
• W2599682072 hasConceptScore W2599682072C2777783956 @default.
• W2599682072 hasConceptScore W2599682072C2779013556 @default.
• W2599682072 hasConceptScore W2599682072C2780820201 @default.
• W2599682072 hasConceptScore W2599682072C2993640289 @default.
• W2599682072 hasConceptScore W2599682072C42219234 @default.
• W2599682072 hasConceptScore W2599682072C71924100 @default.
• W2599682072 hasLocation W25996820721 @default.
• W2599682072 hasOpenAccess W2599682072 @default.
• W2599682072 hasPrimaryLocation W25996820721 @default.
• W2599682072 isParatext "false" @default.
• W2599682072 isRetracted "false" @default.
• W2599682072 magId "2599682072" @default.
• W2599682072 workType "article" @default.